Fulltext

Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations

Simmons, Ruth ; Sharp, Colin ; McClure, C. Patrick ; Rohrbach, Janine ; Kovari, Helen ; Frangou, Eleni ; Simmonds, Peter ; Irving, Will ; Rauch, Andri ; Bowness, Paul ; Klenerman, Paul

In: The Journal of Infectious Diseases, 2012, vol. 205, no. 12, p. 1816-1820

Add to personal list
    Title
    • Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations
    Author
    • Simmons, Ruth. Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research
    • Sharp, Colin. Centre for Immunology, Infection and Evolution
    • McClure, C. Patrick. School of Molecular Medical Sciences, National Institute for Health Research Biomedical Research Unit, University of Nottingham
    • Rohrbach, Janine. University Clinic of Infectious Diseases, University Hospital Bern and University of Bern
    • Kovari, Helen. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland
    • Frangou, Eleni. Department of Statistics, University of Oxford
    • Simmonds, Peter. Centre for Immunology, Infection and Evolution
    • Irving, Will. School of Molecular Medical Sciences, National Institute for Health Research Biomedical Research Unit, University of Nottingham
    • Rauch, Andri. University Clinic of Infectious Diseases, University Hospital Bern and University of Bern
    • Bowness, Paul. Weatherall Institute of Molecular Medicine
    • Klenerman, Paul. Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research
    Document Type
    • Postprint
    Language
    • English
    Published in
    • The Journal of Infectious Diseases, 2012, vol. 205, no. 12, p. 1816-1820. Oxford University Press
    Other Version
    Classification
    • Health
    OAI-PMH Identifier
    • oai:doc.rero.ch:296875
    Summary
    Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV- and HCV-infected individuals (n=469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear